Table 1.
Prevalence of hypertension by characteristics according to the 2018 Chinese/2017 ACC/AHA guideline
| Characteristics | Prevalence | Awarenessa | Pharmaceutical treatmenta | Control | Control among treated hypertensive participants | |||
|---|---|---|---|---|---|---|---|---|
| 2018 Chinese | 2017 ACC/AHA | 2018 Chinese | 2018 Chinese | 2018 Chinese | 2017 ACC/AHA | 2018 Chinese | 2017 ACC/AHA | |
| Overall | 32.0 (30.2‐33.7) | 56.5 (54.2‐58.8) | 49.7 (46.1‐53.3) | 43.4 (39.9‐47.0) | 16.3 (14.0‐18.6) | 9.2 (7.8‐10.5) | 37.6 (35.0‐40.1) | 14.9 (13.4‐16.4) |
| Age | ||||||||
| 35‐44 | 15.0 (13.5‐16.4) | 41.7 (39.4‐43.9) | 31.7 (26.5‐37.0) | 24.5 (19.9‐29.1) | 9.9 (7.0‐12.7) | 3.5 (2.4‐4.6) | 40.3 (35.4‐45.3) | 14.0 (12.2‐15.8) |
| 45‐54 | 29.6 (27.6‐31.6) | 56.1 (53.5‐58.7) | 47.0 (42.9‐51.0) | 40.3 (36.2‐44.3) | 16.1 (13.7‐18.6) | 8.4 (7.1‐9.7) | 40.1 (37.4‐42.8) | 14.2 (12.6‐15.9) |
| 55‐64 | 44.6 (42.4‐46.9) | 67.2 (64.7‐69.7) | 53.9 (50.1‐57.7) | 48.1 (44.3‐51.9) | 18.6 (15.9‐21.2) | 12.2 (10.4‐14.1) | 38.6 (35.5‐41.6) | 16.0 (13.9‐18.1) |
| 65‐74 | 55.7 (53.5‐58.0) | 74.7 (72.4‐77.0) | 58.6 (55.6‐61.7) | 52.8 (49.6‐56.1) | 18.4 (16.2‐20.7) | 13.6 (11.9‐15.4) | 34.9 (32.2‐37.6) | 15.2 (13.2‐17.2) |
| ≥75 | 60.2 (57.7‐62.8) | 78.7 (77.1‐80.2) | 57.3 (53.9‐60.6) | 52.1 (48.4‐55.7) | 17.0 (14.7‐19.4) | 13.0 (11.2‐14.8) | 32.7 (29.9‐35.6) | 13.6 (11.8‐15.3) |
| P value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.092 |
| Sex | ||||||||
| Men | 32.8 (30.9‐34.7) | 61.1 (58.7‐63.4) | 46.1 (42.5‐49.8) | 39.1 (35.7‐42.6) | 14.5 (12.4‐16.7) | 7.8 (6.6‐8.9) | 37.2 (34.6‐39.8) | 14.0 (12.5‐15.4) |
| Women | 31.1 (29.3‐32.8) | 51.9 (49.5‐54.3) | 53.4 (49.7‐57.1) | 48.0 (44.2‐51.9) | 18.2 (15.7‐20.8) | 10.8 (9.2‐12.5) | 37.9 (35.2‐40.6) | 15.7 (14.0‐17.5) |
| P value | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.357 | 0.008 |
| Region | ||||||||
| Eastern | 34.4 (32.2‐36.5) | 60.4 (57.6‐63.1) | 51.9 (46.3‐57.5) | 46.5 (40.7‐52.4) | 18.8 (15.0‐22.6) | 10.6 (8.4‐12.8) | 40.3 (36.5‐44.1) | 16.0 (13.6‐18.4) |
| Middle | 29.9 (25.7‐34.2) | 52.0 (47.9‐56.1) | 53.0 (47.5‐58.6) | 45.4 (40.3‐50.5) | 17.8 (14.8‐20.8) | 10.1 (7.9‐12.4) | 39.2 (36.2‐42.1) | 16.0 (14.1‐18.0) |
| Western | 30.7 (27.6‐33.8) | 55.8 (52.3‐59.2) | 42.1 (37.0‐47.1) | 35.9 (30.8‐41.0) | 10.4 (7.9‐12.9) | 5.7 (4.4‐6.9) | 29.1 (24.9‐33.3) | 10.8 (8.0‐13.7) |
| P value | 0.073 | 0.001 | 0.011 | 0.013 | 0.001 | 0.001 | <0.001 | 0.009 |
| Urban/rural | ||||||||
| Urban | 31.8 (29.2‐34.4) | 55.9 (52.8‐59.0) | 53.9 (48.8‐59.0) | 48.7 (43.5‐53.8) | 20.7 (17.3‐24.0) | 11.7 (9.7‐13.7) | 42.5 (39.2‐45.7) | 16.9 (14.7‐19.0) |
| Rural | 32.0 (29.7‐34.4) | 56.8 (53.6‐60.0) | 47.4 (42.3‐52.5) | 40.6 (35.6‐45.7) | 14.0 (10.8‐17.1) | 7.8 (6.0‐9.7) | 34.4 (30.6‐38.3) | 13.6 (11.5‐15.8) |
| P value | 0.899 | 0.686 | 0.070 | 0.027 | 0.005 | 0.007 | 0.002 | 0.035 |
Data are presented as % (95% CI).
a
Awareness and pharmaceutical treatment based on the 2017 ACC/AHA guideline cannot be estimated in this study.